HUE041981T2 - Eljárások antipszichotikum által kiváltott súlygyarapodás kezelésére - Google Patents

Eljárások antipszichotikum által kiváltott súlygyarapodás kezelésére

Info

Publication number
HUE041981T2
HUE041981T2 HUE11820517A HUE11820517A HUE041981T2 HU E041981 T2 HUE041981 T2 HU E041981T2 HU E11820517 A HUE11820517 A HU E11820517A HU E11820517 A HUE11820517 A HU E11820517A HU E041981 T2 HUE041981 T2 HU E041981T2
Authority
HU
Hungary
Prior art keywords
procedures
weight gain
induced weight
antipsychotic
treating
Prior art date
Application number
HUE11820517A
Other languages
English (en)
Inventor
Daniel Deaver
Mark Todtenkopf
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45723770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE041981(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of HUE041981T2 publication Critical patent/HUE041981T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
HUE11820517A 2010-08-23 2011-08-23 Eljárások antipszichotikum által kiváltott súlygyarapodás kezelésére HUE041981T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37612010P 2010-08-23 2010-08-23

Publications (1)

Publication Number Publication Date
HUE041981T2 true HUE041981T2 (hu) 2019-06-28

Family

ID=45723770

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE18198977A HUE065427T2 (hu) 2010-08-23 2011-08-23 Eljárások antipszichotikum által indukált súlygyarapodás kezelésére
HUE11820517A HUE041981T2 (hu) 2010-08-23 2011-08-23 Eljárások antipszichotikum által kiváltott súlygyarapodás kezelésére

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE18198977A HUE065427T2 (hu) 2010-08-23 2011-08-23 Eljárások antipszichotikum által indukált súlygyarapodás kezelésére

Country Status (20)

Country Link
US (11) US8778960B2 (hu)
EP (3) EP3446565B1 (hu)
JP (1) JP5684388B2 (hu)
AU (4) AU2011293502B2 (hu)
CA (1) CA2807965C (hu)
CY (1) CY1121128T1 (hu)
DK (2) DK2608670T3 (hu)
ES (2) ES2705726T3 (hu)
FI (1) FI3446565T3 (hu)
HR (2) HRP20190169T1 (hu)
HU (2) HUE065427T2 (hu)
LT (2) LT2608670T (hu)
NZ (1) NZ606730A (hu)
PL (2) PL3446565T3 (hu)
PT (2) PT2608670T (hu)
RS (2) RS58312B1 (hu)
SI (2) SI2608670T1 (hu)
SM (2) SMT201900051T1 (hu)
TR (1) TR201900097T4 (hu)
WO (1) WO2012027359A1 (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2445502T (lt) * 2009-06-25 2017-09-25 Alkermes Pharma Ireland Limited Heterocikliniai junginiai, skirti neurologinių ir fiziologinių susirgimų gydymui
TR201908514T4 (tr) 2009-12-04 2019-07-22 Alkermes Pharma Ireland Ltd İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇
US8778960B2 (en) 2010-08-23 2014-07-15 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
ES2770978T3 (es) 2013-05-24 2020-07-06 Alkermes Pharma Ireland Ltd Análogos de morfanos y morfinanos y métodos de uso
EP3003311A2 (en) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
US12527754B2 (en) 2018-06-29 2026-01-20 Tufts Medical Center, Inc. Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
WO2023105103A1 (es) 2022-06-17 2023-06-15 Mesoestetic Pharma Group, S.L Composición cosmética sinérgica despigmentante de la piel

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES252980A1 (es) 1958-10-30 1960-11-01 Boehringer Sohn Ingelheim Procedimiento para la obtencion de nuevas sales cuaternarias, terapéuticamente valiosas, de la normorfina y de sus derivados
BE634402A (fr) 1962-07-02 1964-01-02 British Drug Houses Ltd Dérivés de l'hydrophénanthrène et leurs procédés de préparation
GB981046A (en) 1962-07-02 1965-01-20 British Drug Houses Ltd Hexahydro-4ah-8,9c-iminoethano phenanthro-[4,5-b,c,d]-furan derivatives
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
CH581624A5 (hu) 1970-08-14 1976-11-15 Sumitomo Chemical Co
US3856795A (en) 1972-04-25 1974-12-24 American Home Prod Process for preparation of secondary amines from tertiary amines
DE2254298A1 (de) 1972-11-06 1974-05-16 Boehringer Sohn Ingelheim Neue (heteroarylmethyl)-normorphine, deren saeureadditionssalze, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
US3957793A (en) 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
US4032529A (en) 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US4127577A (en) 1975-11-24 1978-11-28 Sterling Drug Inc. Aminomethanobenzazocine process
US4205171A (en) 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4161597A (en) 1976-12-20 1979-07-17 Research Corporation N-alkyl-14-hydroxymorphinans and derivatives
US4100228A (en) 1977-04-04 1978-07-11 The Dow Chemical Company Transparent impact styrene polymer structure
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4373139A (en) 1979-04-30 1983-02-08 Motorola, Inc. Detectors
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
FR2514644A1 (fr) 1981-10-19 1983-04-22 Sanofi Sa Composition pharmaceutique a action antagoniste peripherique des opiaces
DE3220831A1 (de) 1982-06-03 1983-12-08 Boehringer Ingelheim KG, 6507 Ingelheim N-(2-methoxyethyl)-noroxymorphon, dessen saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu deren herstellung
US4451470A (en) 1982-07-06 1984-05-29 E. I. Du Pont De Nemours And Company Analgesic, antagonist, and/or anorectic 14-fluoromorphinans
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4649200A (en) 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
US4939264A (en) 1986-07-14 1990-07-03 Abbott Laboratories Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
US4929622A (en) 1987-09-24 1990-05-29 Hoechst-Roussel Pharmaceuticals, Inc. 2,6-Methanopyrrolo-3-benzazocines
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5258386A (en) 1991-06-05 1993-11-02 The United States Of America As Represented By The Secretary Of The Army (+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents
US5607941A (en) 1992-06-26 1997-03-04 Boehringer Ingelheim Kg Useful for treating neurodegenerative diseases
SE9103745D0 (sv) 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
JPH05231100A (ja) 1992-02-25 1993-09-07 Hazama Gumi Ltd トンネル用通気仕切り
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
EP0632041A1 (en) 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
CA2474701C (en) 1993-11-19 2009-01-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradeable microparticles containing a biologically active agent
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
ATE229958T1 (de) 1996-01-10 2003-01-15 Glaxosmithkline Spa Heterocyclische kondensierte morphin-derivate
GB9616253D0 (en) 1996-08-01 1996-09-11 Johnson Matthey Plc Preparation of narcotic analgesics
ES2121553B1 (es) 1996-12-23 1999-06-16 Univ Santiago Compostela Nuevos endoperoxidos morfinicos funcionalizados en posiciones c-6 y c-14 del anillo c y procedimiento para su obtencion.
GB9709972D0 (en) 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
EP1210084A4 (en) 1999-08-13 2002-11-13 Southern Res Inst PYRIDOMORPHINANS, THIENOMORPHINANS AND THEIR USE
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
NZ518562A (en) 1999-11-29 2005-04-29 Adolor Corp Novel methods and compositions involving opioids and antagonists thereof
AU2002227135B2 (en) 2000-10-31 2008-01-03 Rensselaer Polytechnic Institute 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
US7375082B2 (en) 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
WO2003079945A1 (en) 2002-03-20 2003-10-02 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
US20050222204A1 (en) 2002-05-30 2005-10-06 Mitch Charles H Opioid receptor antagonists
DE10229842A1 (de) 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
WO2004007449A1 (en) 2002-07-16 2004-01-22 Rensselaer Polytechnic Institute Process for conversion of phenols to carboxamides via the succinimide esters
AU2003298691A1 (en) 2002-11-18 2004-06-15 The Mclean Hospital Corporation Mixed kappa/mu opioids and uses thereof
WO2004071423A2 (en) 2003-02-05 2004-08-26 Euro-Celtique S.A. Methods of administering opioid antagonists and compositions thereof
EP1617832B1 (en) * 2003-04-29 2008-03-12 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
BRPI0506807A (pt) * 2004-04-22 2007-05-29 Mor Research Applic Ltd método de gerenciamento de consumo de alimento e composição farmacológica
AU2005245403B2 (en) 2004-05-14 2012-04-19 Janssen Pharmaceutica N.V. Carboxamido opioid compounds
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
ES2387737T3 (es) * 2004-11-05 2012-10-01 Rensselaer Polytechnic Institute 4-Hidroxibenzomorfanos
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
JP5266051B2 (ja) 2005-07-21 2013-08-21 レンセラール ポリテクニック インスティチュート 大きい置換基を有する非フェノール性オピオイド
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
WO2007067714A2 (en) * 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
WO2007089934A2 (en) 2006-02-01 2007-08-09 Alkermes, Inc. Methods of treating alcoholism and alcohol related disorders using combination drug therapy and swellable polymers
US8115002B2 (en) 2006-09-20 2012-02-14 Mallinckrodt Llc Preparation of substituted morphinan-6-ones and salts and intermediates thereof
AU2007313103C1 (en) 2006-10-17 2014-01-30 Penick Corporation Process for preparing oxymorphone
EP2099456A2 (en) 2006-11-22 2009-09-16 Progenics Pharmaceuticals, Inc. N-oxides of 4,5-epoxy-morphinanium analogs
US9040726B2 (en) 2007-03-06 2015-05-26 Mallinckrodt Llc Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
CA2681506C (en) 2007-03-19 2016-05-24 Perry Peters Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
EP2148864A2 (en) 2007-05-16 2010-02-03 Rensselaer Polytechnic Institute Fused-ring heterocycle opioids
WO2009009083A1 (en) 2007-07-12 2009-01-15 The Mclean Hospital Corporation R(-)-2-methoxy-11-hydroxyaporphine and derivatives thereof
CN101827819B (zh) 2007-08-09 2013-06-12 伦斯勒理工学院 阿片样物质酰胺季铵盐
WO2009103004A1 (en) 2008-02-14 2009-08-20 Alkermes, Inc. Selective opioid compounds
US8138169B2 (en) 2008-04-11 2012-03-20 Comgenrx, Inc. Combination therapy for bipolar disorder
JP5727374B2 (ja) 2008-07-21 2015-06-03 レンセラール ポリテクニック インスティチュート 大型置換基を有する非フェノール性アミンオピオイド
EP3170395A1 (en) 2009-03-19 2017-05-24 Alkermes Pharma Ireland Limited Morphinan derivatives with high oral bioavailability
US20120149724A1 (en) 2009-06-04 2012-06-14 The General Hospital Corporation Modulating endogenous beta-endorphin levels
LT2445502T (lt) 2009-06-25 2017-09-25 Alkermes Pharma Ireland Limited Heterocikliniai junginiai, skirti neurologinių ir fiziologinių susirgimų gydymui
TR201908514T4 (tr) 2009-12-04 2019-07-22 Alkermes Pharma Ireland Ltd İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇
US8436175B2 (en) 2010-03-22 2013-05-07 Rensselaer Polytechnic Institute Carboxamide bioisosteres of opiates
CA2804940C (en) 2010-07-08 2017-03-07 Alkermes Pharma Ireland Limited Process for the synthesis of substituted morphinans
EP2601196B1 (en) 2010-08-04 2014-04-30 Mallinckrodt LLC N-demethylation of 6-keto morphinans
US8778960B2 (en) 2010-08-23 2014-07-15 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
US8987293B2 (en) 2010-12-23 2015-03-24 Phoenix Pharmalabs, Inc. Morphinans useful as analgesics
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
LT3153171T (lt) 2011-12-15 2018-12-10 Alkermes Pharma Ireland Limited Samidorfanas (alks 33) derinyje su buprenorfinu, skirtas depresinių sutrikimų gydymui
EP3003311A2 (en) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
ES2770978T3 (es) 2013-05-24 2020-07-06 Alkermes Pharma Ireland Ltd Análogos de morfanos y morfinanos y métodos de uso

Also Published As

Publication number Publication date
US12194035B2 (en) 2025-01-14
RS65091B1 (sr) 2024-02-29
CA2807965A1 (en) 2012-03-01
JP5684388B2 (ja) 2015-03-11
US11185541B2 (en) 2021-11-30
US20140349999A1 (en) 2014-11-27
AU2011293502B2 (en) 2015-03-19
EP2608670A1 (en) 2013-07-03
PT2608670T (pt) 2019-02-01
AU2015201907A1 (en) 2015-05-07
EP2608670A4 (en) 2014-05-07
TR201900097T4 (tr) 2019-02-21
US20190307742A1 (en) 2019-10-10
US9126977B2 (en) 2015-09-08
FI3446565T3 (fi) 2024-01-30
RS58312B1 (sr) 2019-03-29
PT3446565T (pt) 2024-01-29
US11351166B2 (en) 2022-06-07
US20120077800A1 (en) 2012-03-29
PL2608670T3 (pl) 2019-05-31
DK2608670T3 (en) 2019-02-11
EP3446565A1 (en) 2019-02-27
US10300054B2 (en) 2019-05-28
SI3446565T1 (sl) 2024-03-29
HRP20240109T1 (hr) 2024-03-29
EP2608670B1 (en) 2018-10-31
ES2969625T3 (es) 2024-05-21
PL3446565T3 (pl) 2024-04-02
US10716785B2 (en) 2020-07-21
HUE065427T2 (hu) 2024-05-28
NZ606730A (en) 2015-05-29
US11241425B2 (en) 2022-02-08
JP2013536239A (ja) 2013-09-19
SMT202400030T1 (it) 2024-03-13
CA2807965C (en) 2016-03-15
US20210015812A1 (en) 2021-01-21
EP4306164A3 (en) 2024-03-20
HRP20190169T1 (hr) 2019-03-22
US8778960B2 (en) 2014-07-15
DK3446565T3 (da) 2024-01-22
AU2017200396B2 (en) 2018-04-19
US20210038594A1 (en) 2021-02-11
US20180271855A1 (en) 2018-09-27
US9517235B2 (en) 2016-12-13
SI2608670T1 (sl) 2019-04-30
AU2015201907B2 (en) 2016-12-22
LT2608670T (lt) 2019-01-25
US9943514B2 (en) 2018-04-17
AU2017200396A1 (en) 2017-02-09
EP3446565B1 (en) 2023-11-01
EP4306164A2 (en) 2024-01-17
US20170119757A1 (en) 2017-05-04
US11793805B2 (en) 2023-10-24
US20210046065A1 (en) 2021-02-18
AU2018202410B2 (en) 2019-02-28
AU2011293502A1 (en) 2013-02-28
WO2012027359A1 (en) 2012-03-01
US20240293394A1 (en) 2024-09-05
US20220280502A1 (en) 2022-09-08
US20160051538A1 (en) 2016-02-25
LT3446565T (lt) 2024-01-10
ES2705726T3 (es) 2019-03-26
CY1121128T1 (el) 2019-12-11
SMT201900051T1 (it) 2019-02-28
AU2018202410A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
NL301198I2 (nl) enfortumab vedotin
EP2595532A4 (en) IMPLANTABLE DIELECTROMETER
EP2609148A4 (en) PHTHALIC ACID-FREE SOFT MAKER
DK2542189T3 (da) Håndprotese
PT3412687T (pt) Métodos de tratamento de dlbcl
DK2542201T3 (da) Kropsunderstøttende platform
EP2433335A4 (en) Connector
EP2537530A4 (en) RADIATION MEANS
EP2595881A4 (en) TAIL BEAM IN THE FORM OF AERODYNAMIC PROFILE
HUE041981T2 (hu) Eljárások antipszichotikum által kiváltott súlygyarapodás kezelésére
EP2613438A4 (en) AMPLIFIER
EP2621497A4 (en) ASSOCIATION TREATMENT FOR ROSE ACNE
EP2535065A4 (en) DIALYSIS MACHINE
EP2613409A4 (en) Connector
HRP20160929T1 (hr) Terapijski režimi
EP2571161A4 (en) AMPLIFIER
EP2584655A4 (en) CONNECTOR
EP2554140A4 (en) STENT
EP2604228A4 (en) STENT
FR2965717B1 (fr) Fauteuil roulant
FR2965715B1 (fr) Fauteuil roulant
FR2959664B1 (fr) Plot podo-tactile
DE102010060608A8 (de) Verstellvorrichtung
FR2956127B1 (fr) Plot podotactile
ES1073355Y (es) No consta